Ohki Seiya, Fukuda Mei, Baba Tomoyo, Wakayama Naomi, Morio Hanae, Ito Shingo, Ohtsuki Sumio, Yamaura Yoshiyuki, Komori Takafumi, Furihata Tomomi
Laboratory of Clinical Pharmacy & Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, 192-0392, Japan.
Global Drug Metabolism and Pharmacokinetics, Tsukuba Research Laboratories, Eisai Co. Ltd., Ibaraki, 300-2635, Japan.
Drug Metab Pharmacokinet. 2025 Jun;62:101058. doi: 10.1016/j.dmpk.2025.101058. Epub 2025 Feb 20.
In vitro blood-brain barrier (BBB) models, primarily consisting of brain microvascular endothelial cells (BMEC), are expected to play pivotal roles in evaluating drug permeability into the brain. However, these models often exhibit functional variability due to various factors, raising practical concerns that can hinder their use in drug development studies. By investigating cell passage numbers as one such factor, we aim to assess how BBB model functionality is affected and to propose a practical strategy for managing this variability. In transwell-BBB models - but not in spheroidal-BBB models - the intercellular barrier integrity was somewhat compromised when higher-passage human immortalized BMEC (HBMEC/ci18) were used. Nonetheless, a clear in vitro-in vivo correlation (IVIVC) curve could still be obtained with these transwell-BBB models, similar to those with lower passage number HBMEC/ci18, presumably allowing for reasonable estimation of in vivo drug permeability. Therefore, changes in functional levels of BBB models do not always significantly diminish their practical value in drug BBB permeability studies. Additionally, the IVIVC curve integrity may serve as an indicator for assessing acceptable BBB model functionality. These findings provide valuable insights for the future application of in vitro human BBB models in drug development studies.
体外血脑屏障(BBB)模型主要由脑微血管内皮细胞(BMEC)组成,有望在评估药物向脑内的渗透性方面发挥关键作用。然而,由于各种因素,这些模型常常表现出功能变异性,引发了一些实际问题,可能会阻碍它们在药物研发研究中的应用。通过将细胞传代次数作为此类因素之一进行研究,我们旨在评估血脑屏障模型功能是如何受到影响的,并提出一种管理这种变异性的实用策略。在transwell - BBB模型中,但在球形BBB模型中并非如此,当使用传代次数较高的人永生化BMEC(HBMEC/ci18)时,细胞间屏障完整性会受到一定程度的损害。尽管如此,这些transwell - BBB模型仍能获得清晰的体外 - 体内相关性(IVIVC)曲线,类似于使用传代次数较低的HBMEC/ci18所获得的曲线,大概能够合理估计体内药物渗透性。因此,血脑屏障模型功能水平的变化并不总是会显著降低它们在药物血脑屏障渗透性研究中的实际价值。此外,IVIVC曲线的完整性可作为评估血脑屏障模型功能是否可接受的一个指标。这些发现为体外人血脑屏障模型在药物研发研究中的未来应用提供了有价值的见解。